TROPION - Lung10
Brief Summary
The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced or metastatic non-squamous NSCLC with high PD-L1 expression (TC ≥ 50%) and without actionable genomic alterations.
Official Title
A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for the First-line Treatment of Participants With Locally-advanced or Metastatic Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations (NCT06357533)
Conditions
Non-Small Cell Lung Cancer
Copernicus
Brief Summary
The primary purpose of the study is to assess how well amivantamab in combination with lazertinib or in combination with chemotherapy works (antitumor activity) in participants with epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC; that is one of the major types of lung cancer).
Official Title
A Study of Amivantamab in Combination With Lazertinib or Platinum-Based Chemotherapy for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NCT06667076)
Conditions
Carcinoma, Non-Small-Cell Lung
TRITON Trial
Brief Summary
The purpose of the study is to assess the efficacy of durvalumab plus tremelimumab in combination with chemotherapy compared with pembrolizumab in combination with chemotherapy in metastatic NSCLC patients with non-squamous histology who have mutations and/or co-mutations in STK11, KEAP1, or KRAS.
Official Title
A Phase III, Randomized, Double-Blind Study to Assess Durvalumab Plus Tremelimumab in Combination With Chemotherapy vs Pembrolizumab With Chemotherapy in Patients With Metastatic Non-Small Cell Lung Cancer With Certain Genetic Mutations (NCT06008093)
Conditions
Non-Small Cell Lung Cancer (NSCLC)
ARTEMIDE - Lung03
Brief Summary
The purpose of ARTEMIDE-Lung03 is to evaluate the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a first-line treatment of patients with non-squamous mNSCLC whose tumors express PD-L1.
Official Title
A Phase III, Randomized, Double-Blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-Line Treatment of Patients With Metastatic Non-squamous Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 (NCT06627647)
Conditions
Early-Stage Lung Cancer
ARTEMIDE - Lung02
Brief Summary
The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with metastatic squamous non-small cell lung cancer (mNSCLC) whose tumors express programmed death-ligand 1 (PD-L1).
Official Title
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 (NCT06692738)
Conditions
Non-small Cell Lung Cancer
BE6A Lung-02
Brief Summary
The purpose of the study is to compare how the new combination treatment (Sigvotatug Vedotin plus pembrolizumab) works compared to pembrolizumab alone in patients with non-small cell lung cancer (NSCLC) with high levels of PD-L1. This is a protein that acts as a kind of "brake" to keep the body's immune responses under control.
Official Title
An Open-label, Randomized, Controlled Phase 3 Study of Sigvotatug Vedotin in Combination With Pembrolizumab Compared With Pembrolizumab Monotherapy as First-Line Treatment in Participants With PD-L1 High, Locally Advanced or Metastatic Non Small Cell Lung Cancer (NCT06758401)
Conditions
Non-Small Cell Lung Cancer , Carcinoma, Non-Small-Cell Lung
Artemide - Lung 02
Brief Summary
The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with metastatic squamous non-small cell lung cancer (mNSCLC) whose tumors express programmed death-ligand 1 (PD-L1) (NCT06692738).
Official Title
A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung02)
Conditions
Advanced Non-Small Cell Lung Cancer (NSCLC)
Krascendo‑2 Study
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of divarasib and pembrolizumab compared with pembrolizumab and pemetrexed and carboplatin or cisplatin, for the first-line treatment of adult participants with KRAS G12C-mutated, advanced or metastatic non squamous non-small cell lung cancer (NSCLC).
Official Title
A Phase III, Randomized, Open‑Label Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Patients With Previously Untreated, KRAS G12C‑Mutated, Advanced or Metastatic Non‑Squamous Non-Small Cell Lung Cancer (NCT06793215)
Conditions
Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
